By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Genentech (Oceanside) 

One Antibody Way

Oceanside  California  92056  U.S.A.
Phone: 760-231-2440 Fax: n/a


SEARCH JOBS
Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:
http://www.youtube.com/genentech#p/u/1/GJH4X5gxxf0

Connect with us via Social Media:

Facebook: www.facebook.com/GenentechJobs

Twitter: www.twitter.com/GenentechJobs

LinkedIn: www.linkedin.com/company/genentech


Key Statistics


Email:
Ownership: Subsidiary

Web Site: Genentech (Oceanside)
Employees: 10,000+
Symbol: RHHBY
 



Industry
Biotechnology

Segment
Biotherapeutics





Company News
SurModics Inc. (SRDX) Enters Ophthalmic License and Development Agreement with Roche (RHHBY) (JOBS) and Genentech (South SF) (DNA) (JOBS); SurModics Could Receive Up to Approximately $200 Million 10/6/2009 6:31:37 AM
Genentech, Inc. (DNA) Release: Xeloda(R)-Oxaliplatin Combination (XELOX) Shown to Be More Effective Than Standard Chemotherapy Regimen in Adjuvant Colon Cancer 7/20/2009 10:16:14 AM
New Data from OSI Pharmaceuticals, Inc. (OSIP) (JOBS), Genentech, Inc. (Oceanside) (DNA) (JOBS) Phase III SATURN Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer 7/13/2009 6:32:20 AM
Genentech, Inc. (DNA): Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion 7/6/2009 9:46:53 AM
Facebook Taps Ex-Genentech, Inc. (Oceanside) (DNA) CFO for Finance Chief 6/30/2009 8:44:30 AM
Sangamo BioSciences, Inc. (SGMO) Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech, Inc. (DNA) 6/29/2009 8:49:25 AM
Biogen Idec, Inc. (Massachusetts) (BIIB) Announces Conclusion of Arbitration with Genentech, Inc. (DNA) 6/17/2009 7:46:09 AM
Bayhill Therapeutics, Inc. Enters Exclusive, Worldwide Collaboration with Genentech, Inc. (DNA) (JOBS) for BHT-3021 in Type 1 Diabetes; Deal Could Potentially Exceed $350M 6/10/2009 7:22:53 AM
Genentech, Inc. (DNA) Release: Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Advanced Breast Cancer 5/29/2009 8:32:36 AM
Genentech, Inc. (DNA) And Biogen Idec, Inc. (California) (BIIB) Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia 5/20/2009 9:25:21 AM
123
//-->